Clinical Trials
34
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 94
- Registration Number
- NCT06839131
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, China
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 170
- Registration Number
- NCT06487455
- Locations
- 🇨🇳
XiangYa Hospital CentralSouth University, Changsha, China
🇨🇳Fujian Cancer Hospital, Fuzhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, China
A Clinical Study of SPH7854 Granules in Healthy Subjects.
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 111
- Registration Number
- NCT06483373
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, China
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
- Conditions
- Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06434597
- Locations
- 🇨🇳
Beijing Friendship Hospital，Capital Medical University, Beijing, China
🇨🇳Chinese PLA General hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Food Effect Study of SPH5030 Tablets.
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06372223
- Locations
- 🇨🇳
West China Second Hospital ,Sichuan University, Chengdu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Lumosa Therapeutics' LT3001 Shows Promise in Phase II Acute Ischemic Stroke Trial
Lumosa Therapeutics' LT3001 demonstrated a robust safety profile and tolerability in a Phase II clinical trial for acute ischemic stroke patients.